295357-66-3

Usage

Uses

Used in Pharmaceutical Industry:
2-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)glutaric acid is used as a building block for the development of new drugs and treatments. Its unique chemical structure and properties make it a promising candidate for the creation of innovative pharmaceutical compounds.
Used in Medical Research:
2-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)glutaric acid is used as a research tool for studying neurodegenerative diseases and psychiatric disorders. Its chemical properties allow for the investigation of various biological processes and mechanisms related to these conditions.
Used in Organic Synthesis:
2-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)glutaric acid is used as a key intermediate in the synthesis of complex organic molecules. Its versatile structure enables the formation of a wide range of compounds with diverse applications.
Used in Materials Science:
2-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)glutaric acid has potential applications in the development of new materials with unique properties. Its chemical structure may contribute to the creation of advanced materials for various industries.

Upstream product

• 295357-79-8 1-(4-nitro-1-oxoisoindolin-2-yl)propane-1,3-dicarboxylic acid dibenzyl ester 
• 1198299-50-1 dimethyl 2-(4-amino-2,3-dihydro-1-oxo-1H-isoindol-2-yl)glutarate 
• 98475-07-1 2-bromomethyl-3-nitro-benzoic acid methyl ester 
• 59382-59-1 2-methyl-3-nitro-benzoic acid methyl ester 
• 827026-43-7 2-(4-nitro-1-oxo-1,3-dihydroisoindol-2-yl)glutaric acid dimethyl ester 
• 295357-72-1 2-(4-nitro-1-oxo-1,3-dihydroisoindol-2-yl)glutaric acid 

Downstream Products

• 1198299-64-7 3-[4-(N-benzyloxycarbonyl)amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl]glutaric anhydride 
• 879126-98-4 Lenalidomide 

Relevant academic research and scientific papers

Preparation method of lenalidomide

A preparation method of lenalidomide comprises the following steps: 1, reacting a raw material methyl 2-methyl-3-nitro-benzoate with a halogenating reagent to obtain methyl 2-halomethyl-3-nitro-benzoate represented by formula (I); 2, reacting the methyl 2-halomethyl-3-nitro-benzoate with dimethyl D,L-glutamate hydrochloride in the presence of an alkaline compound to obtain dimethyl 3-(7-nitro-1-oxo-1,3-dihydroisoindole-2-yl)glutarate represented by formula (II); 3, hydrolyzing the above compound of formula (II) to obtain 3-(7-nitro-1-oxo-1,3-dihydroisoindole-2-yl)glutaric acid represented by formula (III); 4, reducing the above compound of formula (III) to obtain 3-(7-amino-1-oxo-1,3-dihydroisoindole-2-yl)glutaric acid represented by formula (IV); and 5, carrying out ring closure on the above compound of formula (IV) to obtain lenalidomide represented by formula (V). The method has the advantages of simple process, high safety, cheap and easily available raw materials, good quality of the above product, and suitableness for industrial production.

METHODS FOR SYNTHESIZING 3-(SUBSTITUTED DIHYDROISOINDOLINONE-2-YL)-2,6-DIOXOPIPERIDINE, AND INTERMEDIATES THEREOF

The present invention discloses methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2,6-dioxopiperidine and intermediates thereof, namely, the synthesis of compounds of the Formula (I), with each substitutional group defined in the patent specification. Owing to the advantages of high productivity, little influence to the environment and material accessibility, the methods of the present invention is suitable for industrial production.

Substituted 1-oxo- and 1,3-dioxoisoindoline and method of reducing inflammatory cytokine levels

1-Oxo- and 1,3-dioxoisoindolines substituted in the 4- or 5-position of the indoline ring reduce the levels of inflammatory cytokines such as TNFα in a mammal. A typical embodiment is 4-(4-amino-1,3-dioxoisoindolin-2-yl)-4-carbamoylbutanoic acid.